BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, December 6, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 12, 2014

View Archived Issues

Pearl Therapeutics presents first clinical data for PT-010

Read More

CytRx begins phase Ib trial of aldoxorubicin and ifosfamide or mesna

Read More

biOasis advances lysosomal storage disease program

Read More

Roche characterizes novel alpha7-nAChR PAM

Read More

Collaboration leads to state-dependent Na(v)1.7 inhibitors for the treatment of pain

Read More

rAvPAL-loaded erythrocytes as enzyme replacement therapy for phenylketonuria

Read More

Cellceutix updates on i.v. brilacidin trial and submits IND for oral rinse formulation

Read More

Aurigene Discovery Technologies divulges novel BTK inhibitors

Read More

GlaxoSmithKline discloses novel RIP-1 inhibitors

Read More

Allergan presents new S1P1 receptor modulators

Read More

Merck & Co. synthesizes new Kir1.1 channel blockers

Read More

Kala Pharmaceuticals patents novel VEGFR-2 inhibitors

Read More

Meiji Seika presents a novel antifungal with improved efficacy against dermatophytes

Read More

CURx Pharmaceuticals licenses Captisol-formulated lamotrigine from Ligand Pharmaceuticals

Read More

Eli Lilly and Boehringer Ingelheim's insulin glargine biosimilar approved in E.U.

Read More

Mimetogen releases topline data from phase III dry eye study of MIM-D3

Read More

Serodus reports phase IIa data on SER-100 in patients with systolic hypertension

Read More

NIAAA to study gabapentin enacarbil for the treatment of alcohol use disorder

Read More

Transparency Life Sciences receives grant to support phase IIa trial of lisinopril in MS

Read More

First clinical results for 2B3-201 as potential new treatment for acute relapses in MS

Read More

Senesco Technologies changes name to Sevion Therapeutics

Read More

MabVax Therapeutics receives stockholder approval for name change

Read More

Dovobet ointment launched in Japan

Read More

SRI International and Nobelpharma sign licensing agreement on SR-16234 for endometriosis

Read More

FDA approves Contrave for chronic weight management

Read More

Baxter International to name biopharmaceutical entity Baxalta

Read More

FDA advisory committee recommends approval of liraglutide for obesity

Read More

Rhodiola rosea extract proves beneficial for stress-induced sexual dysfunction in rodents

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 5, 2025.
  • 3D rendering of prion structure

    Epigenetic technology could eliminate misfolded prion proteins

    BioWorld Science
    The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
  • Mesothelin is biomarker, potential target in arthritic bone damage

    BioWorld Science
    In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
  • Male hair loss

    Cosmo data positive for first new hair-loss approach in decades

    BioWorld
    Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing